Return to study ST001467 main page
MB Sample ID: SA124418
Local Sample ID: | BST100_4m |
Subject ID: | SU001541 |
Subject Type: | Mammal |
Subject Species: | Mus musculus |
Taxonomy ID: | 10090 |
Select appropriate tab below to view additional metadata details:
Subject:
Subject ID: | SU001541 |
Subject Type: | Mammal |
Subject Species: | Mus musculus |
Taxonomy ID: | 10090 |
Factors:
Local Sample ID | MB Sample ID | Factor Level ID | Level Value | Factor Name |
---|---|---|---|---|
BST100_4m | SA124418 | FL015055 | batch2 | Group |
BST100_4m | SA124418 | FL015055 | BST204 | Treatment |
BST100_4m | SA124418 | FL015055 | muscle | Sample Source |
Collection:
Collection ID: | CO001536 |
Collection Summary: | Mice were randomized into five groups (n = 10 each): untreated, non-tumor-bearing mice (NTB group); untreated, tumor-bearing mice (TB group); tumor-bearing mice receiving 5-FU (5-FU group); tumor-bearing mice receiving 5-FU and 100-mg/kg BST204 (BST204100 group); and tumor-bearing mice receiving 5-FU and 200-mg/kg BST204 (BST204200 group). CT26 murine colon carcinoma cells (1 × 106) (Korean Cell Line Bank, Seoul, Korea) resuspended in 100 μL of phosphate-buffered saline were subcutaneously implanted in the right flank of 8-week-old BALB/c mice (Orient Bio, Seongnam, Korea). When tumor volumes reached 100–200 mm3 (approximately 10 days after tumor cell injection), day 0 was assigned and drug administration started for 5-FU and BST204 groups. BST204 (batch number 31037/H1) was obtained from Green Cross Wellbeing (Seongnam, South Korea), and 5-FU was purchased from Sigma-Aldrich (St. Louis, MO, USA). 5-FU (50 mg/kg) was injected intraperitoneally in 3-day cycles (1st cycle: days 0–2; 2nd cycle: days 6–8), in doses that did not exceed the clinically acceptable. BST204 (100 or 200 mg/kg) was orally administered in 5-day cycles (1st cycle: days 0–4; 2nd cycle: days 6–10). The BST204 doses were determined according to its effects on chemotherapy-related fatigue and toxicity. The endpoint of our study was determined according to IACUC guidelines, which recommend euthanasia with a maximum tumor volume of 1,500 mm3 and a BW loss of 20%. Therefore, our study period was limited to day 11. At this point, the change in tumor volumes was up to 810%, and significant cachexia was observed. |
Sample Type: | Blood (plasma) |
Collection Location: | muscle |
Storage Conditions: | -20℃ |
Treatment:
Treatment ID: | TR001556 |
Treatment Summary: | Mice were randomized into five groups (n = 10 each): untreated, non-tumor-bearing mice (NTB group); untreated, tumor-bearing mice (TB group); tumor-bearing mice receiving 5-FU (5-FU group); tumor-bearing mice receiving 5-FU and 100-mg/kg BST204 (BST204100 group); and tumor-bearing mice receiving 5-FU and 200-mg/kg BST204 (BST204200 group). CT26 murine colon carcinoma cells (1 × 106) (Korean Cell Line Bank, Seoul, Korea) resuspended in 100 μL of phosphate-buffered saline were subcutaneously implanted in the right flank of 8-week-old BALB/c mice (Orient Bio, Seongnam, Korea). When tumor volumes reached 100–200 mm3 (approximately 10 days after tumor cell injection), day 0 was assigned and drug administration started for 5-FU and BST204 groups. BST204 (batch number 31037/H1) was obtained from Green Cross Wellbeing (Seongnam, South Korea), and 5-FU was purchased from Sigma-Aldrich (St. Louis, MO, USA). 5-FU (50 mg/kg) was injected intraperitoneally in 3-day cycles (1st cycle: days 0–2; 2nd cycle: days 6–8), in doses that did not exceed the clinically acceptable. BST204 (100 or 200 mg/kg) was orally administered in 5-day cycles (1st cycle: days 0–4; 2nd cycle: days 6–10). The BST204 doses were determined according to its effects on chemotherapy-related fatigue and toxicity. The endpoint of our study was determined according to IACUC guidelines, which recommend euthanasia with a maximum tumor volume of 1,500 mm3 and a BW loss of 20%. Therefore, our study period was limited to day 11. At this point, the change in tumor volumes was up to 810%, and significant cachexia was observed. |
Treatment: | 5-FU was injected intraperitoneally in 3-day cycles. BST204 was orally administerd in 5-day cycles. |
Treatment Compound: | 5-FU, BST204 |
Treatment Dose: | 5-FU (50 mg/kg), BST204 (100 or 200 mg/kg) |
Animal Endp Euthanasia: | study period was limited by day 11 |
Sample Preparation:
Sampleprep ID: | SP001549 |
Sampleprep Summary: | Metabolites related to glucose-mediated energy metabolism were extracted using LLE. Amino acids and bioamines were also extracted using LLE and underwent chemical derivatization with phenylisothiocyante. |
Processing Storage Conditions: | 4℃ |
Extraction Method: | Liquid Liquid Extraction (LLE) |
Combined analysis:
Analysis ID | AN002443 |
---|---|
Analysis type | MS |
Chromatography type | Reversed phase |
Chromatography system | Agilent 1290 |
Column | Zorbax Eclipse XDB-C18 (100 x 2mm) |
MS Type | ESI |
MS instrument type | Triple quadrupole |
MS instrument name | ABI Sciex 5500 QTrap |
Ion Mode | POSITIVE |
Units | area ratio |
Chromatography:
Chromatography ID: | CH001788 |
Chromatography Summary: | Metabolites related to glucose-mediated metabolites were analyzed with LC-MS/MS (MRM) |
Instrument Name: | Agilent 1290 |
Column Name: | Synergi fusion RP (50 x 2mm) |
Column Temperature: | 23 |
Flow Gradient: | 0% B for 5 min, 0% to 90% B for 2 min, hold at 90% B for 8 min, 90% to 0% B for 1 min, and then hold at 0% B for 9 min |
Flow Rate: | 70 μL/min except for minutes 7 to 15, when it was 140 µL/min |
Internal Standard: | 13C5-glutamine |
Sample Injection: | 3 uL |
Solvent A: | 100% water; 5 mM ammonium acetate |
Solvent B: | 100% acetonitrile; 5 mM ammonium acetate |
Chromatography Type: | Reversed phase |
Chromatography ID: | CH001789 |
Chromatography Summary: | Amino acids and bioamines were analyzed with LC-MS/MS (MRM) |
Instrument Name: | Agilent 1290 |
Column Name: | Zorbax Eclipse XDB-C18 (100 x 2mm) |
Column Temperature: | 50 |
Flow Gradient: | 0% B for 0.5 min, 0% to 95% B for 5 min, hold at 95% B for 1 min, 95% to 0% B for 0.5 min, then hold at 0% B for 2.5 min |
Flow Rate: | 500 μL/min |
Internal Standard: | 13C5-glutamine, serotonine-d4, dopamine-d4, tryptophan-d5, serine-d3, and lysine-d8 |
Sample Injection: | 3 uL |
Solvent A: | 100% water; 0.2% formic acid |
Solvent B: | 100% acetonitrile; 0.2% formic acid |
Chromatography Type: | Reversed phase |
MS:
MS ID: | MS002267 |
Analysis ID: | AN002443 |
Instrument Name: | ABI Sciex 5500 QTrap |
Instrument Type: | Triple quadrupole |
MS Type: | ESI |
MS Comments: | Amino acids and bioamines MRM mode Analyst 1.52 |
Ion Mode: | POSITIVE |